Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Sector: Medical
CLEVELAND BIOLABS (NASDAQ: CBLI)
3m
6m
1y
2y
Ranking History
This Week
Last Week
Two Weeks Back
Three Weeks Back
Please login to view our current ranking data
Click here to login
No Information
No Information
No Information
Disclaimer
Headlines
Blog Articles
Premium News
Press Releases
SEC
Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
Nov 18, 2009 09:28 AM |
CBLI
Cleveland BioLabs to Present at Merriman 6th Annual Investor Summit
Nov 02, 2009 08:30 AM |
CBLI
Cleveland BioLabs to Host Roundtable on Protectan CBLB502 for Acute Radiation Syndrome
Oct 20, 2009 08:30 AM |
CBLI
Cleveland BioLabs to Present at 8th Annual BIO Investor Forum
Oct 19, 2009 08:30 AM |
CBLI
Department of Defense Increases Ongoing Contract With Cleveland BioLabs for Developmental Studies Related to Protectan CBLB502
Oct 06, 2009 08:31 AM |
CBLI
Rodman & Renshaw Initiates Analyst Coverage of Cleveland BioLabs
Oct 05, 2009 08:30 AM |
CBLI
,
RODM
Armed Forces Radiobiology Research Institute and Cleveland BioLabs Awarded Grant From Department of Defense to Study Radioprotective Effects of Protectan CBLB600 Series
Sep 30, 2009 11:39 AM |
CBLI
Cleveland BioLabs Awarded $5.3 Million Grand Opportunities Grant From National Institutes of Health for Protectan CBLB502 Research in Mitigation of Radiation Damage of GI Tract
Sep 29, 2009 08:30 AM |
CBLI
Cleveland BioLabs Receives $2.3 Million Addition to $13.3 Million Contract With Biomedical Advanced Research and Development Authority (BARDA) to Develop Radiation Countermeasure Protectan CBLB502
Sep 24, 2009 09:56 AM |
CBLI
National Institute of Allergy and Infectious Diseases Awards Cleveland BioLabs Additional Grant for Protectan CBLB502 Research in Mitigation of Radiation Damage
Sep 22, 2009 08:31 AM |
CBLI
More..
Big Rebound Puts Some Spring Back in Local Stocks: Buffalo Portfolio Gained 17.6 Percent As Market Rallied in the Second Quarter
Jul 05, 2009 11:54 AM |
ATRO
,
CBLI
,
CTGX
,
FISI
Big Rebound Puts Some Spring Back in Local Stocks: Buffalo Portfolio Gained 17.6 Percent As Market Rallied in the Second Quarter
Jul 05, 2009 07:52 AM |
ATRO
,
CBLI
,
CTGX
,
FISI
Cleveland BioLabs Nears Big Investment
May 22, 2009 07:55 AM |
CBLI
Cleveland BioLabs Raises $2.9 Million
Mar 24, 2009 04:52 PM |
CBLI
BRIEF: Cleveland BioLabs Raises Money for Radiation Medicine
Mar 23, 2009 04:52 PM |
CBLI
Local Stocks Drop 31.1% in 2008 ; Only 3 of 22 End Year With a Gain
Jan 04, 2009 10:14 PM |
ATRO
,
BUF
,
CBLI
,
FNFG
,
GB
Local Stocks Drop 31.1% in 2008
Jan 04, 2009 10:14 AM |
ATRO
,
BUF
,
CBLI
,
FNFG
,
GB
,
II
More..
Cleveland BioLabs Receives First U.S. Patent Allowance for Its Radiation Protection Drug Protectan CBLB502
Aug 17, 2009 09:23 AM |
CBLI
Department of Defense Releases Further Funding to Cleveland BioLabs Under $8.8 Million Contract for Development Studies on Protectan CBLB502
Jul 01, 2009 08:01 AM |
CBLI
Cleveland BioLabs Management Reviews Recent Highlights and Milestones at Annual Meeting
Jun 25, 2009 11:00 AM |
CBLI
Cleveland BioLabs Concludes Initial Phase I Safety and Tolerability Study for CBLB502
Jun 03, 2009 08:01 AM |
CBLI
Cleveland BioLabs Submits Response to Department of Defense Sources Sought Notice for Radiological and Nuclear Medical Countermeasures
May 28, 2009 09:42 AM |
CBLI
Cleveland BioLabs Signs Term Sheet for Joint Venture to Develop Curaxin Compounds for Cancer Applications
May 21, 2009 08:30 AM |
CBLI
Oncogene Publishes Cleveland BioLabs Paper on Mechanism of Action of Curaxins
May 18, 2009 08:31 AM |
CBLI
Cleveland BioLabs Formally Terminates Boston Stock Exchange Listing
May 15, 2009 02:30 PM |
CBLI
Cleveland BioLabs Updates Financial Condition Following Completion of Private Placement and Streamlining of Operations
Apr 09, 2009 04:00 PM |
CBLI
Cleveland BioLabs Concludes Private Placement of Series D Preferred Stock and Common Stock Warrants
Mar 30, 2009 08:30 AM |
CBLI
More..
Form 4 CLEVELAND BIOLABS INC For: Nov 16 Filed by: Gudkov Andrei V (10K)
Nov 17, 2009 04:53 PM
Form 4 Kogan Yakov For: Nov 02 (10K)
Nov 03, 2009 05:03 PM
Form 4 CLEVELAND BIOLABS INC For: Oct 22 Filed by: Fonstein Michael (10K)
Oct 23, 2009 05:54 PM
Form 4 CLEVELAND BIOLABS INC For: Oct 16 Filed by: Gudkov Andrei V (10K)
Oct 19, 2009 06:19 PM
Form 4 Kogan Yakov For: Oct 01 (10K)
Oct 02, 2009 05:51 PM
Form 4 Fonstein Michael For: Sep 22 (10K)
Sep 23, 2009 06:29 PM
Form 4 Gudkov Andrei V For: Sep 16 (10K)
Sep 17, 2009 06:36 PM
Form 4 Kogan Yakov For: Sep 01 (10K)
Sep 02, 2009 05:48 PM
Form 4 Fonstein Michael For: Aug 24 (10K)
Aug 25, 2009 06:04 PM
Form 4 Perez Hector Daniel For: Jun 25 (10K)
Jun 26, 2009 06:03 PM
More..
Analyst Ratings
More Details
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
CBLI
Compare to S&P
YTD
83.10 %
51.24 %
4 Weeks
-15.58 %
-16.03 %
12 Weeks
-11.56 %
-17.01 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
-0.01 %
EPS Growth in Last Year:
-0.01 %
Sales Growth in Last Quarter:
-22.97 %
Sales Growth in Last Quarter:
74.05 %
More...
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
